Stock Scorecard
Stock Summary for Adverum Biotechnologies Inc (ADVM) - $9.72 as of 5/1/2024 3:11:15 PM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ADVM
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ADVM
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ADVM
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for ADVM
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for ADVM
Financial Details for ADVM
Company Overview |
|
|---|---|
| Ticker | ADVM |
| Company Name | Adverum Biotechnologies Inc |
| Country | USA |
| Description | Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 6/7/2024 |
Stock Price History |
|
| Last Day Price | 9.72 |
| Last Day Price Updated | 5/1/2024 3:11:15 PM EST |
| Last Day Volume | 0 |
| Average Daily Volume | 534,410 |
| 52-Week High | 29.70 |
| 52-Week Low | 7.40 |
| Last Price to 52 Week Low | 31.35% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 60.82 |
| Sector PE | 53.36 |
| 5-Year Average PE | -19.42 |
| Free Cash Flow Ratio | 2.09 |
| Industry Free Cash Flow Ratio | 19.61 |
| Sector Free Cash Flow Ratio | 30.86 |
| Current Ratio Most Recent Quarter | 4.13 |
| Total Cash Per Share | 4.65 |
| Book Value Per Share Most Recent Quarter | 8.23 |
| Price to Book Ratio | 2.92 |
| Industry Price to Book Ratio | 7.49 |
| Sector Price to Book Ratio | 22.00 |
| Price to Sales Ratio Twelve Trailing Months | 67.63 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.43 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.14 |
Share Statistics |
|
| Total Shares Outstanding | 20,754,900 |
| Market Capitalization | 201,737,628 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 24.18% |
| Reported EPS 12 Trailing Months | -11.60 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -3.23 |
| Net Income Twelve Trailing Months | -117,165,000 |
| Net Income Past Year | -117,165,000 |
| Net Income Prior Year | -154,536,000 |
| Quarterly Revenue Growth YOY | -70.00% |
| 5-Year Revenue Growth | 17.10% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 96,500,000 |
| Total Cash Past Year | 96,500,000 |
| Total Cash Prior Year | 185,600,000 |
| Net Cash Position Most Recent Quarter | 96,500,000 |
| Net Cash Position Past Year | 96,500,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 100,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 83,469,000 |
| Total Stockholder Equity Prior Year | 181,518,000 |
| Total Stockholder Equity Most Recent Quarter | 83,469,000 |
Options |
|
| Put/Call Ratio | 0.50 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.43 |
| MACD Signal | -1.35 |
| 20-Day Bollinger Lower Band | 4.28 |
| 20-Day Bollinger Middle Band | 13.10 |
| 20-Day Bollinger Upper Band | 21.93 |
| Beta | 0.79 |
| RSI | 21.86 |
| 50-Day SMA | 13.61 |
| 200-Day SMA | 39.40 |
System |
|
| Modified | 5/1/2024 4:38:59 PM EST |